AstraZeneca’s Global Technology Centre in India increases its focus on driving innovation – repositioning
AstraZeneca’s Global Technology Centre in India increases its focus on driving innovation – repositioning itself as a Global Innovation and Technology Centre
Chennai, April 06, 2022: AstraZeneca India Private Limited (AZIPL), the Global Capability Centre (GCC) of Ast raZeneca announced today that they have repositioned their Global Technology Centre (GTC) to focus on drivi ng increased innovation, resulting in a rebrand of the centre to Global Innovation and Technology Centre (GITC).
Over the last eight years, the GTC in Chennai has consistently delivered market-leading IT services and capabili ties for AstraZeneca’s global business. Since inception, the centre has evolved its offering from that of traditio nal IT services, into a critical engine for AstraZeneca’s digital journey and ongoing source of technology innova tion.
The Chennai centre has played a key role in driving productivity, simplification, technology delivery and innovati on across AstraZeneca’s business and in support of life-changing medicines delivered to patients worldwide. The rebranding marks the centre’s evolution of capabilities, commitment to driving innovation and moving the com pany towards a digitally-enabled future. 
Cindy Hoots, Chief Digital Office and CIO, AstraZeneca, said, “We live in an era where the possibilities of digital and technology to transform the lives of patients and the healt hcare sector, are limitless. Our centre in Chennai continues to play a strategic role in our digital transformation, workin g on Visualisation, Data & Analytics, Hyp er automation, X R/VR Capabilities, among other areas. These technologies and innovations play a key role in helping us to advance our science, anticipate patient needs, and work seaml essly across our organization. I am thrilled to see that the work delivered by the team in Chennai is being refl ected in our transition from GTC to GITC.”
Siva Padmanabhan, Managing Director, AstraZeneca India Private Limited (AZIPL), said: “The healthcare and life sciences industry is facing unprecedented challenges and opportunities. Over the last few years, we have succes sfully expanded our skillset and expertise from providing IT services, to becoming a pivotal global centre driving innovation and transformation. With close to 2,800 highly skilled employees, GITC is now one of the largest te chnology centres across the Life Sciences industry in the country. The strong collaboration we have been able to build between industry, academia and the government has helped us in our pursuit of enabling smart capabi litie s at scale across the company’s value chain. Our GITC aims to bring the best of technology, innovation and peo p le to the forefront, to address the ever-evolving healthcare and technology landscape. The rebranding is a powe rful acknowledgement of the strategic importance our Chennai centre plays in our global operations.”
Both AZIPL centres in Chennai and Bengaluru foster a culture of lifelong learning that has been instrumental in AstraZeneca being recognised as a Great Place To Work across consecutive years. The entity brings together the brightest minds and cutting-edge resources, making AstraZeneca an employer of choice that attracts talent to deliver meaningful, purpose-driven work in a highly inclusive environment. Both centres offer employees a posit ive, physiologically safe, productive and collaborative work culture with ample opportunities for personal growt h and expansion.
About AstraZeneca India Private Limited
AstraZeneca India Pvt. Ltd. (AZIPL) is the services arm for AstraZeneca with offices in Chennai and Bengaluru. Established in 2014, AZIPL today has close to 3000 employees catering to services including IT services, Global Business Services (GBS) and R&D Oncology among others. The entity plays a key role in technology innovation and transformation projects enabling and empowering AstraZeneca’s core business processes – from Discovery, Development, Production, Launches to Supply all the way through the value chain. www.astrazeneca.com/india
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases across our main disease are as: Oncology; BioPharmaceuticals (including Cardiovascular, Renal & Metabolism, and Respiratory & Immunolo gy); and Rare Disease. AstraZeneca operates in over 100 countries, and its innovative medicines are used by mill ions of patients worldwide.
